Progression of CAR-T trials in China

Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, gives an overview of the current CAR T-cell trial activities in China. Prof. Wang highlights the progression of the bispecific CAR-T targeting CD19 and CD22 and the BCMA and CD19 bispecific CAR-T, both manufactured in the FasT CAR-T platform. A novel TCR-based extracellular complex, STAR (synthetic TCR and antigen receptor), is being investigated in China. STAR T-cells may have improved persistence after infusion. Lastly, Prof. Wang discusses a new CD7-CAR T-cell product against T-cell malignancies. This interview took place during the 3rd European CAR T-cell Meeting.

Тэги:

#Speaker:_Jianxiang_Wang #Event:_CAR-T_Meeting_2021 #Event:_VJVirtual #Institution:_Institute_of_Hematology_&_Blood_Diseases_Hospital #Format:_Interview #Subject:_Leukemia #Subject:_Acute_Lymphoblastic_Leukemia #Subject:_Multiple_Myeloma #Field:_Immuno-Oncology #Field:_Treatment #Medicines:_CAR-T #CD19 #CD20 #CD38 #STAR-T #CD7 #BCMA #Specialty:_Oncology #Specialty:_Hematology #Technology:_CAR_T-Cell_Therapy #Technology:_Gene-Based_Medicine #Technology:_Cell_Therapy

Скачать видео